Sweden
BICO is a biotechnology startup founded in 2016, specializing in life science solutions and laboratory automation. The company's mission is to facilitate the development of new treatments with greater specificity and less reliance on animal testing. Operating under the umbrella of bioconvergence, BICO combines advanced technologies with biology to optimize workflows within the pharmaceutical and biopharma industries.
With 32,000+ instruments installed in over 65 countries and utilized in more than 3,500 laboratories, including those of the world’s top 20 pharmaceutical companies, BICO has garnered recognition, being cited in over 11,000 publications. The company's three business areas – Bioprinting, Biosciences, and Bioautomation – reflect its commitment to addressing the world’s organ shortage and accelerating drug development to advance life-saving treatments.
Although specific headquarters information is not provided, BICO is listed on Mid-Cap, Nasdaq Stockholm under the ticker symbol BICO, signifying its presence in the stock market. While the details of the last investment and the involved investors are not available, BICO's innovative approach and impactful presence in the life sciences and biotechnology industries position it as an intriguing prospect for potential investors seeking exposure to these sectors.
